Clinical trials: Precision Treatment
Hepatocellular Carcinoma
The AI Prognostic Assessment and Pathological Basis Research of Early HCC After Minimally Invasive Treatment
The study evaluates artificial intelligence method based on multimodal magnetic resonance imaging (MRI) images and clinical data in preoperative prediction of prognosis in early hepatocellular carcinoma (HCC) patients treated…
- Trial name
- NCT04299919
- Testing
- Minimally invasive treatment, Hepatectomy
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- The First Affiliated Hospital of Dalian Medical University
IgA Nephropathy (IgAN), Henoch Schönlein Purpura Nephritis
To Assess the Efficacy and Safety of Utilizing Galactose-deficient IgA1 Biomarker Changes to Guide Pathogenic IgA-targeted Therapeutic Strategies
The goal of this open-label, randomized study is to evaluate the efficacy and safety of the personalized treatment model in which Gd-IgA1 is dynamically monitored to guide medication adjustment in progressive IgAN patients…
- Trial name
- NCT07822100
- Testing
- Gd-IgA1 monitoring
- Where
- China
- Volunteers
- 374 people
- Sponsor
- Hong Zhang
Heart Failure
Virtual Human Twins as Tools for Personalized Clinical Care in Heart Failure With Preserved Ejection Fraction: a Pilot Study
Heart failure (HF) is a heterogeneous clinical syndrome characterized by substantial inter-individual variability in pathophysiology and response to treatment.
- Trial name
- VITAL-HF (NCT07902453)
- Testing
- Data collection for the development and validation of the cardiovascular virtual human twin
- Where
- 2 sites in France
- Volunteers
- 60 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Breast Cancer
Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular Subtyping
To explore the efficacy and safety of Everolimus (SNF1 subtype) or Fluzoparib (SNF3 subtype) combined with Fulvestrant and Abemaciclib vs.
- Trial name
- abemaSNF1/3 (NCT06561022)
- Testing
- Fluzoparib, Everolimus, Fulvestrant
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Fudan University
Solid Tumor
A MolEcularly Guided Anti-Cancer Drug Off-Label Trial
This is a prospective, open-label, non-randomized combined basket- and umbrella trial divided in two parts; a limited feasibility-oriented part 1 including 154 patients and 3 treatment cohorts and part 2 that will include an…
- Trial name
- MEGALiT (NCT04185831)
- Testing
- Atezolizumab, Everolimus, Cobimetinib
- Where
- 3 sites in Sweden
- Volunteers
- 167 people
- Sponsor
- Uppsala University Hospital
High-grade Serous Ovarian Carcinoma (HGSOC)
Artificial Intelligence-guided Precision Treatment of High-grade Serous Ovarian Carcinoma
The subjects of this study are patients with high-grade serous ovarian cancer who have undergone surgical resection. The aim is to construct an artificial intelligence model for predicting postoperative recurrence, metastasis and…
- Trial name
- AI-PTHGSOC (NCT07721675)
- Testing
- No Intervention: Observational Cohort
- Volunteers
- 1,300 people
- Sponsor
- The Affiliated Hospital of Qingdao University
Solid Tumor, Precision Medicine
Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion
The main purpose of this study is to explore the feasibility of selecting treatment plans based on genomic variations guided by MTB in patients with advanced refractory solid tumors.
- Trial name
- NCT06739395
- Testing
- Olaparib tablet, Temozolomide capsule, Anlotinib
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Tianjin Medical University Second Hospital
Solid Tumor, Gastric Cancer
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors
This study was planned as an open-label, multi-site, Phase I/IIa dose escalation, safety, and pharmacokinetic (PK) trial of BNT141 followed by expansion cohorts in patients with Claudin 18.2 (CLDN18.2)-positive tumors.
- Conditions
- Solid Tumor, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- NCT04683939
- Testing
- BNT141, Nab-paclitaxel, Gemcitabine
- Where
- 7 sites in United States, Canada
- Volunteers
- 13 people
- Sponsor
- BioNTech SE
Breast Carcinoma
CAREFOR: Precision Medicine Driving Precision Nutrition for the Treatment of NeoAdjuvant Breast Cancer
The purpose of the study is to determine if a targeted dietary change can enhance the effect of neo-adjuvant chemotherapy
- Trial name
- NCT02827370
- Testing
- Behavioral Dietary Intervention
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Coronary Artery Disease
Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention
The proposed study aims to assess the antiplatelet effects of more potent oral P2Y12 inhibition with low-dose ticagrelor (60 mg bid) compared with standard of care clopidogrel in patients with a high ABCD-GENE score (≥10).
- Trial name
- NCT06228456
- Testing
- Ticagrelor 60mg, Clopidogrel
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Florida
Non-small Cell Lung Cancer (NSCLC), EGFR-TKI Resistant Mutation
A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment
For patients of advanced NSCLC (non small cell lung cancer) , Individualized cancer therapy has been widely accepted since the success of crizotinib administration based on EML4-ALK fusion gene detection and gefitinib and…
- Conditions
- Non-small Cell Lung Cancer (NSCLC), EGFR-TKI Resistant Mutation, EGFR-TKI Sensitizing Mutation, Germline Mutations
- Trial name
- NCT01994057
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Sun Yat-sen University
Coronary Artery Disease, Percutaneous Coronary Intervention
Precision PCI Registry
The feasibility and clinical benefit of using a patient's genotype to guide antiplatelet therapy prescribing has been demonstrated.
- Trial name
- NCT06143709
- Testing
- DNA sample collection
- Where
- United States
- Volunteers
- 1,643 people
- Sponsor
- University of Florida
Parkinson's Disease
Therapeutic Potential for Intranasal Levodopa in Parkinson's Disease -Off Reversal
A Phase IIa, Randomized, Double Blind, Placebo Controlled, Single Dose, Safety and Pharmacokinetic/Pharmacodynamic Study of INP103 (POD L-dopa) Administered in the Presence of Decarboxylase Inhibitor to L-dopa Responsive…
- Trial name
- THOR201 (NCT03541356)
- Testing
- L-dopa 35 mg, L-dopa 70mg, L-dopa 140 mg
- Where
- 5 sites in Australia
- Volunteers
- 32 people
- Sponsor
- Impel Pharmaceuticals
Post-stroke Depression
A Study of rTMS Personalized Precision Treatment of Post-stroke Depression
This is a multicenter, randomized trial aims to reveal the efficacy and safety of Repetitive transcranial magnetic stimulation (rTMS) individualized therapy based on the 'emotional loop destabilization' mechanism of PSD .One…
- Trial name
- NCT03256305
- Testing
- "personalized" rTMS+drug treatment, Traditional rTMS +drug treatment
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Zhujiang Hospital
HCC
Precision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma
Vessels that encapsulate tumor clusters (VETC) is an invasive metastatic factor in HCC independent of the epithelial mesenchyme transition (EMT), and VETC-positive patients have a higher rate of postoperative recurrence.
- Trial name
- NCT06311929
- Testing
- PD-1 monoclonal antibody and lenvatinib, PD-1 monoclonal antibody
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Chen Xiaoping
Hypertension, Dyslipidemia
A Novel Digital Tool Clinicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors
The investigators will conduct a feasibility and pilot efficacy randomized controlled trial to test the usability and user satisfaction of an evidence-based digital health tool the investigators developed for clinicians to use to…
- Conditions
- Hypertension, Dyslipidemia, Diabetes Mellitus, Obesity
- Trial name
- P3-EX (NCT07238556)
- Testing
- Experimental - 12 Week P3-EX Unsupervised Exercise Program with Virtual Weekly Oversight from Graduate Research Assistants, Active Control - 12 Week ACSM-PAVS Unsupervised Exercise Program with Virtual Weekly Oversight from Graduate Research Assistants
- Where
- 3 sites in United States
- Volunteers
- 72 people
- Sponsor
- University of Connecticut
Triple-negative Breast Cancer
FUSCC Refractory TNBC Umbrella (FUTURE)
This is a Phase Ib/II, open-label, multi-center umbrella study evaluating the efficacy and safety of multiple targeted treatment in patients with refractory metastatic TNBC.The specific grouping of patients' depends on FUSCC 500+…
- Trial name
- FUTURE (NCT03805399)
- Testing
- Pyrotinib with Capecitabine, AR inhibitor combined with everolimus(B1) or CDK4/6 inhibitor(B2),or EZH2 inhibitor (B4), anti PD-1 with nab-paclitaxel
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Fudan University
Severe Community-acquired Pneumonia (sCAP)
Randomized Adaptive Platform Trial of Pathogen-Directed Anti-inflammatory Therapy in Severe Community-Acquired Pneumonia(Core Protocal)
Severe community-acquired pneumonia (sCAP) has a high mortality rate of 25-50%. Excessive host inflammatory responses contribute to poor outcomes.
- Trial name
- PANDA-SCAP (NCT07152587)
- Testing
- Low dose steroids, Moderate dose steroids, Saline (0.9% NaCl)
- Volunteers
- 1,500 people
- Sponsor
- Qingyuan Zhan
Inflammatory Bowel Diseases, Crohn Disease
MOdel-Informed Precision Dosing of Ustekinumab and VEdolizumab in Inflammatory Bowel Disease
The goal of this clinical trial is to investigate if dosage of Ustekinumab (UST) and Vedolizumab (VDZ) based on Model-Informed Precision Dosing (MIPD) is equally as efficient in keeping adults with Inflammatory Bowel Disease…
- Conditions
- Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
- Trial name
- MOVE-IT (NCT06788340)
- Testing
- PK-model to decide when to dose Vedolizumab and Ustekinumab
- Where
- 6 sites in Denmark
- Volunteers
- 166 people
- Sponsor
- Odense University Hospital
Extensive Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma, A Subtype
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
This phase II trial tests how well biomarker tests on patients tumor tissue works in selecting personalized treatments for patients with extensive stage small cell lung cancer (ES-SCLC).
- Conditions
- Extensive Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma, A Subtype, Lung Small Cell Carcinoma, I Subtype, Lung Small Cell Carcinoma, N Subtype
- Trial name
- NCT06769126
- Testing
- Biospecimen Collection, Ceralasertib, Computed Tomography
- Where
- 148 sites in United States
- Volunteers
- 900 people
- Sponsor
- SWOG Cancer Research Network